Test Catalog

Test ID: EBNA2    
Epstein Barr Nuclear Antigen 2 (EBNA2) Immunostain, Technical Component Only

Useful For Suggests clinical disorders or settings where the test may be helpful

Identification of Epstein Barr virus infection in normal, inflammatory, and neoplastic tissues

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

For the initial technical component only immunohistochemical (IHC) stain performed, the appropriate bill-only test ID will be reflexed and charged (IHTOI). For each additional technical component only IHC stain performed, an additional bill-only test ID will be reflexed and charged (IHTOA).

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Epstein Barr virus (EBV) nuclear antigen 2 (EBNA2) is an EBV-encoded nuclear protein of 82 kD. EBNA2 is necessary for transformation of EBV-infected B lymphocytes and has been shown to modulate the activity of several viral and cellular promoters. This immunostain may be useful in the diagnosis of reactive and neoplastic lymphoproliferative and plasma cell proliferative disorders.

Interpretation Provides information to assist in interpretation of the test results

This test does not include pathologist interpretation; only technical performance of the stain. If interpretation is required, order PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case.


The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request, call 855-516-8404.


Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen-dependent. Best practice is for paraffin sections to be cut within 6 weeks.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Wood CD, Carvell T, Gunnell A, et al: Enhancer control of microRNA miR-155 expression in Epstein-Barr virus-infected B cells. J Virol. 2019 Jan 17;93(3):e01893-18. doi: 10.1128/JVI.01893-18

2.  Anastasiadou E, Stroopinsky D, Alimperti S, et al: Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia. 2019;33:132–147

3. Hudnall SD, Ge Y, Wei L, et al: Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils. Mod Pathol. 2005;18:519-527